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Abstract
Purpose—To describe cytomegalovirus (CMV) end-organ disease (EOD) rate in AIDS patients
with low CD4+ cell count despite HAART who were enrolled in a randomized, placebo-controlled
trial of preemptive valganciclovir (VGCV) to prevent CMV EOD in those with CMV viremia.
Methods—Subjects (N = 338) were HIV-infected with CD4+ count <100 cells/mm3, plasma HIV
RNA >400 copies/mL, and on stable or no HAART. All underwent plasma CMV DNA PCR testing
every 8 weeks (Step 1); those with detectable CMV DNA were randomized to VGCV or placebo
(Step 2).
Results—Plasma CMV DNA was detected in 68 (20%), of whom 4 developed CMV EOD. During
Step 1, 53 died. Of the 47 who entered Step 2 (24 VGCV, 23 placebo), CMV EOD was diagnosed
in 10 (4 VGCV, 6 placebo) and 15 died (7 VGCV, 8 placebo). Of those randomized to placebo, 14%
were diagnosed with CMV EOD at 12 months.
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Conclusions—We observed a lower CMV EOD rate among subjects receiving HAART than
predicted based on published literature. However, mortality was high in this study. Our findings
suggest that preemptive anti-CMV therapy in patients with persistently low CD4+ cell counts in the
current treatment era may not be warranted given the low incidence of CMV EOD and high all-cause
mortality observed in this study population.
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Cytomegalovirus (CMV) infection is present in 50% to 95% of HIV-infected individuals in
the United States. During advanced AIDS, CMV can produce debilitating end-organ disease
(EOD) including retinitis, colitis, and pneumonitis.1–4 Prior to the advent of highly active
antiretroviral therapy (HAART), detection of CMV in the blood was strongly associated with
development of CMV EOD and mortality.5,6 Subsequent to the development of HAART,
several studies of patients receiving these potent regimens demonstrated that detection of CMV
viremia continued to be predictive of CMV EOD, with CMV viremia producing a 40% to 60%
increased risk of CMV EOD.7–11 Further, CMV viremia has also been associated with
heightened risk of mortality – including death not directly related to CMV EOD – in patients
prescribed HAART.10,11
The enhanced risk of CMV EOD among individuals with HIV infection and CMV viremia led
us to conduct a randomized clinical trial of a strategy of preemptive therapy for CMV EOD in
patients with suboptimally controlled HIV disease and CMV viremia and therefore at
heightened risk for disease due to this opportunistic infection. This strategy entailed regular
screening for CMV viremia followed by treatment with oral valganciclovir (VGCV) versus
placebo among those with detectable CMV viremia.
Although participants were HIV-infected patients with profound CD4+ cell depletion and
uncontrolled HIV viremia despite widespread use of HAART, the rate of CMV EOD during
the study was substantially lower than that seen in earlier studies of HAART-receiving patients,
which led to the halting of the trial by an independent data and safety monitoring board during
a scheduled interim review. We describe the rate of CMV EOD and mortality among this cohort
of patients.
METHODS
Study Design and Eligibility
A5030 was a prospective, double-blind, placebo-controlled, randomized trial. Subjects were
CMV seropositive (IgG), were without evidence of CMV EOD, and had a CD4+ cell count
<100 cells/mm3 and plasma HIV RNA > 400 copies/mL within 30 days prior to entry. Subjects
must either have been receiving HAART continuously for 3 months or not be receiving and
not planning to initiate HAART, which was defined as at least a three-drug antiretroviral
regimen, including at least one protease inhibitor (PI) and/or non-nucleoside reverse
transcriptase inhibitor (NNRTI). Subjects on a three-drug nucleoside reverse transcriptase
inhibitor (NRTI) regimen were eligible if treated in the past with a PI or an NNRTI. HAART
was prescribed as part of usual clinical care and not determined by the study protocol. The HIV
treatment criteria were designed to lead to the enrollment of patients who for various reasons,
such as viral resistance and/or medication nonadherence, were not receiving maximal benefit
from HAART and thus were most likely to be at risk of CMV EOD.
The study proceeded in three steps. Subjects entered Step 1 and underwent plasma CMV DNA
PCR measurements every 8 weeks. Subjects who were CMV DNA PCR positive at entry or
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during follow-up were eligible to enter Step 2 and be randomized 1:1 to treatment with VGCV
or placebo. Subjects who developed CMV EOD during Steps 1 or 2 were able to enter Step 3
during which subjects with CMV retinitis were offered open-label VGCV.
The institutional review boards at each participating study site approved the protocol, and all
participants provided verbal and written informed consent.
Study Treatment
Subjects entering Step 2 were randomized to receive VGCV 900 mg or matching placebo orally
administered (po) twice daily after a meal for 3 weeks. Originally, this induction phase was
followed by 900 mg daily of study drug for 9 weeks and then 450 mg daily thereafter. However,
pharmacokinetic studies that became available during the study indicated that the area under
the curve of ganciclovir achieved by VGCV at 450 mg daily is significantly less than that
achieved by standard oral ganciclovir dosing of 1 g by mouth three times a day. Therefore,
from June 2004 onward, the 900 mg daily dose continued after induction without a subsequent
decrease in dose; subjects receiving 450 mg of VGCV daily had the dose increased to 900 mg
daily.
Study Evaluations
CMV viremia assay—Quantitative plasma CMV DNA PCR was performed every 8 weeks
during Step 1 using COBAS Amplicor CMV Monitor assay (Roche Diagnostics, Indianapolis,
Indiana, USA; lower limit of detection of 400 copies/mL). Results were provided to sites in
real time and reported as either detectable or undetectable.
HIV viremia assay—Quantitative plasma HIV RNA PCR (standard or ultrasensitive HIV-1
RT PCR; Roche Diagnostics. Indianapolis, Indiana, USA; lower limits of detection of 400 or
50 copies/mL, respectively) was obtained at Step 1 baseline.
CD4+ cell count—Lymphocyte subsets were obtained at Step 1 baseline, at entry into Step
2 and every 16 weeks thereafter, and at entry into Step 3.
Safety laboratories—Blood chemistries and hematology were obtained at Step 1 baseline
and the latter every 16 weeks during Step 1. Chemistry and hematology laboratories were
collected at Step 2 entry and Weeks 2, 4, 6, 8, 10, and 12 and every 4 weeks thereafter. Adverse
events were graded according to the National Institutes of Health (NIH) Division of AIDS
Table for Grading Adult Adverse Experiences.12
Ocular examinations—Subjects underwent dilated indirect ophthalmoscopy every 8 weeks
during Steps 1 and 2. Subjects with suspected CMV retinitis underwent wide-angle fundus
photographs using techniques established by the National Eye Institute–supported Studies for
the Ocular Complications of AIDS (SOCA) research group.13 All photographs were reviewed
by a central reading center at the University of Wisconsin where the examiners were unaware
of the subject’s step or treatment assignment.
CMV EOD assessment—Subjects were evaluated for symptoms of ocular and extra-ocular
CMV disease at 8-week intervals during Steps 1 and 2. A targeted examination for CMV EOD
was performed when symptoms of CMV EOD were detected. Symptoms suspicious for CMV
EOD were reported to study site clinician for further evaluation. Criteria for probable and
confirmed CMV EOD were established prior to the initiation of the study (Appendix 1).
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Sample size for primary endpoints
The primary endpoint was time-to-CMV EOD (combined probable and confirmed) among
subjects randomized to VGCV versus placebo on Step 2. Based on previously published data,
it was estimated that 40% of subjects randomized to the placebo arm would develop CMV
EOD by 1 year. Further, the study team determined that for preemptive therapy to be considered
clinically viable, the incidence of CMV EOD with therapy needed to be reduced by at least
75% (i.e., a reduction in incidence from 40% to 12% or hazard ratio [HR] of 4.0). Given these
assumptions, to achieve 80% power with a two-sided alpha of 0.05, a sample size of 60 subjects
entering Step 2 would be required. Based on estimated rates of CMV DNA PCR positivity, the
targeted Step 1 sample size was approximately 350 subjects.
Statistical methods
The primary endpoint was tested with a Cox proportional hazards likelihood ratio test stratified
by whether subjects were CMV DNA PCR positive at Step 1 entry. For the primary analysis,
subjects were censored at death without CMV EOD. Results were confirmed with cumulative
incidence analysis incorporating competing risks.14
Study monitoring
This trial was monitored at least annually by an independent Data and Safety Monitoring Board
(DSMB) appointed by National Institutes of Allergy and Infectious Diseases (NIAID). In June
2005, it was determined that it was very unlikely that the study would reach the primary
objective due to the dramatic fall in the rate of subjects in Step 1 developing detectable CMV
DNA to qualify for Step 2 and the unexpectedly low rate of endpoints on the placebo arm.
Accrual to both steps would have had to increase prohibitively to detect a clinically meaningful
effect size in the face of these observed rates. Thus, the DSMB recommended that follow-up
be stopped. No safety issues were identified.
RESULTS
Subject Characteristics and Disposition
A total of 338 subjects were enrolled in Step 1 between August 2000 and April 2004. At study
entry, subjects generally had advanced AIDS with a median CD4+ cell count of 30/mm3. As
expected given the entry criteria, subjects had poorly controlled HIV viremia with only 1%
having a plasma HIV RNA level <400 copies/mL, even though more than 80% were currently
receiving HAART (Table 1). The subject disposition at the time the study was halted by the
DSMB is detailed in Figure 1.
CMV Viremia and Rate of CMV EOD
During a median follow-up of 81 weeks, plasma CMV DNA was detected in 68 (20%) subjects,
including 20 with detectable virus at Step 1 entry or within 8 weeks after entry. The median
time from entry to first detection of CMV viremia among those who were CMV DNA PCR
positive after Week 8 was 46 weeks. The median CMV viral load at first detection was 656
copies/mL (range 400–19,500).
Of the 68 subjects who had CMV DNA detected, 4 (5.8%) were diagnosed with CMV EOD
after detection of viremia but prior to randomization to VGCV or placebo. The median time
from viremia to EOD for these four participants was 6.1 weeks (range 3.0–34.1 weeks). Among
the 270 subjects in Step 1 without detected CMV viremia, 6 (2.2%) were diagnosed with CMV
EOD. Therefore, during Step 1, 10 of the 338 subjects developed CMV EOD (8 retinitis, 1
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colitis, and 1 pancreatitis), just 4 of whom had CMV viremia detected prior to the diagnosis
of EOD.
The median study entry CD4+ cell count of those with CMV viremia detected during Step 1
was 13.5/mm3 compared to 38/mm3 for those who remained aviremic (i.e., CMV DNA PCR
always negative). The median CD4+ cell count just prior to first positive CMV DNA PCR was
10.5/mm3 (range 0–77), and 65% of subjects with detected CMV DNA were reportedly
receiving HAART at entry.
Among the 144 who remained on Step 1 without CMV EOD or becoming CMV DNA PCR
positive, median CD4+ cell counts increased from 38/mm3 at entry to 81.5/mm3 at last study
visit – a median of 137 weeks later. Initiation of HAART during the study was limited: only
six subjects who were not receiving HAART at entry were prescribed HAART during Step 1
and there was minimal antiretroviral modification.
CMV EOD After Randomization to VGCV versus Placebo
Of the 68 subjects with CMV DNA detected during Step 1, 47 entered Step 2. Of those not
entering Step 2, as described above, four (5.8%) were diagnosed with CMV EOD and three of
these subjects directly entered Step 3 while the other subject discontinued study participation.
Seventeen (25%) remaining subjects discontinued study participation. Major reasons for
premature Step 1 discontinuation among viremic subjects included death (four subjects) and
use of prohibited medications such as foscarnet for herpes simplex (five subjects). A variety
of other causes (i.e., severe debility, withdrawal of consent, moved from study area) accounted
for the remainder.
The Step 2 subjects had similar characteristics to the overall study population at entry to Step
1 except the median CD4+ cell count was lower (12/mm3 vs. 30/mm3) (Table 1). Of the subjects
entering Step 2, 24 were randomized to VGCV and 23 to placebo. The first 13 of 24 subjects
randomized to VGCV initiated maintenance therapy with 450 mg daily following the induction
phase. Of these 13, six had the dose of VGCV increased to 900 mg daily following amendment
of the protocol. These six subjects received the 450-mg maintenance dose of VGCV for a
median of 93.9 weeks (range 13.3–175.1 weeks). The remaining seven subjects who initiated
with the lower dose of VGCV completed the study prior to the availability of the
pharmacokinetic data that prompted the dose adjustment.
Median on study follow-up during Step 2 was 54.7 weeks (range 5.7–228.7 weeks). Ten Step
2 subjects were diagnosed with CMV EOD (four on VGCV [two and two while receiving
VGCV 450-mg or 900-mg maintenance dose, respectively] and six on placebo); the estimated
HR was 0.5 and the stratified Cox proportional hazards (PH) likelihood ratio test p value was .
29 (p = .29 for CMV EOD in the cumulative incidence analysis). However, the low number
of CMV EOD endpoints reduced the statistical power to detect a significant difference between
the study arms. Of note, the estimated EOD rate at 1 and 2 years in the placebo arm was 14%
and 39%, respectively.
Of the Step 2 subjects developing CMV EOD, the median CD4+ cell count just prior to
diagnosis was 8/mm3 (range 2–84), and 7 of the 10 were receiving HAART at the time of CMV
EOD diagnosis.
VGCV was well-tolerated and the rates of adverse events, including hematological
abnormalities, experienced by the subjects in the Step 2 study arms (VGCV vs. placebo) were
similar.
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During Step 1, 53 subjects died, including 4 with CMV detected by DNA PCR prior to death.
Median time from viremia to death was 8.8 weeks (range 2.8–13.6 weeks). The majority of
deaths during Step 1 were associated with progression of HIV disease. AIDS wasting or AIDS
itself was listed as the cause of death in 24.5%, bacterial infections in 17%, Pneumocystis
jirovecii pneumonia in 9.4%, AIDS-related malignancies in 7.5%, and Kaposi’s sarcoma in
3.8%. Other non-AIDS-associated causes of death included cardiovascular disease in 9.4%,
non-AIDS-associated malignancies in 5.7%, and pulmonary diseases, pulmonary embolism,
renal failure, and pancytopenia among the remainder. In 17%, the cause of death was not
known. No deaths were considered directly related to CMV EOD.
There were 15 deaths during Step 2: 7 in the VGCV arm and 8 in the control group. The causes
of death in this step were also largely a consequence of infectious complications (none directly
related to CMV) of AIDS wasting or AIDS itself (40%) and bacterial infections (20%), with
liver failure, lupus, and AIDS-associated malignancy accounting for the remainder. The
median CD4+ cell count just prior to death during Step 1 was 10/mm3 (range 0–135) and for
Step 2 was 5/mm3 (range 0–33).
DISCUSSION
In a cohort of HIV-infected individuals at risk for CMV EOD, we found a lower incidence of
CMV disease than was anticipated based on prior published reports. Previous HAART era
studies observed rates of CMV EOD among patients with advanced HIV infection of
approximately 40% or greater. Casado and colleagues reported a 12-month incidence rate of
38% among CMV viremic HAART-treated patients compared to 2% among aviremic patients,
7 and remarkably similar results were found in a French study.8 In the United States, Erice and
colleagues found that in a cohort of patients with AIDS, over 85% receiving HAART, the
estimated 1-year cumulative incidence of CMV EOD among those with CMV DNA detected
in plasma was 50%. In contrast, we observed a 12-month incidence rate of 14% among CMV
viremic HAART-treated subjects compared to 1% among aviremic subjects. Even when
considering the 68 subjects with detectable plasma CMV DNA during Step 1 who did not
receive VGCV during Step 2, the 12-month rate of CMV EOD was 22%.
The reason for the relatively low rate of CMV EOD in this trial is unclear. CD4+ cell counts
increased only modestly during the trial, and a large proportion of subjects continued to have
very low CD4+ cell counts that should have placed them at risk for CMV disease.7 Why
subjects maintained low CD4+ cell counts during this study is also unclear and is likely a
function of viral resistance cultivated during prior antiretroviral regimens, suboptimal
immunological response to current HAART, and mediation nonadherence. Inadequate
adherence to HAART, especially older and less convenient combination therapies, is common
in clinical practice. This study did not supply HAART and did not include an intervention to
enhance compliance with HIV treatment. Rather, the study was designed to determine whether
a strategy of preemptive anti-CMV therapy would be effective in preventing CMV EOD in
modern-era patients considered to be at continued risk of this opportunistic disease.
The lower incidence of CMV EOD in this study compared to studies conducted in the pre-
HAART era could be explained in part by HAART-related improvements in immune function
not measurable by quantitative CD4+ count that have afforded protection against CMV disease.
It is noteworthy that among subjects in Step 1, rates of detection of CMV by PCR fell
dramatically over time; no subject in Step 1 had CMV viremia detected in the final 10 months
of the study.
Wohl et al. Page 6













The low number of outcomes makes it difficult to arrive at firm conclusions regarding the
efficacy of preemptive VGCV. However, these findings do suggest that the strategy of
preemptive VGCV for CMV EOD prevention is unlikely to provide benefit, because the risk
of such disease is now so small.
Although the incidence of CMV EOD was low, mortality was high among these subjects. There
were 53 deaths while subjects were on Step 1 (16%) and 24% of all subjects entering this study
eventually died during the trial, most due to AIDS-related causes and disease not related to
CMV. Suboptimal adherence to HAART and/or accumulated viral drug resistance likely drove
mortality in this cohort. The high mortality rate may also have contributed to the low incidence
of CMV EOD, as these are competing events. Patients with advanced AIDS, most at risk for
CMV EOD, are also at greatest risk for other opportunistic conditions, many of which can
cause severe debility or death. The study intervention was limited to prevention of CMV EOD,
however standard prophylaxis for opportunistic infections was permitted. In previous studies,
CMV viremia has been associated with increased risk of death.7–9,11 In this trial, mortality in
the VGCV and placebo arms was very similar.
There are a number of limitations to this investigation. Several subjects developed CMV EOD
without preceding detectable plasma CMV DNA, and CMV viremia may have occurred
transiently between study evaluations and may have been missed by intermittent sampling.
Additionally, adherence to antiretroviral therapy was not assessed and under-treatment of HIV
disease could have been a driving force for CMV EOD, other opportunistic conditions, and
death. It should be noted that patients such as those enrolled in this trial may be increasingly
uncommon given the expanded number of antiretroviral options available, their enhanced
convenience, and their relative potency. Therefore, as antiretroviral therapy advances in terms
of efficacy and tolerability, fewer HIV-infected patients will remain at risk for CMV disease.
In summary, a strategy of CMV viremia screening and preemptive VGCV initiation in patients
such as those studied who had low CD4+ cell counts despite receiving HAART appears not to
be warranted given the low incidence of CMV EOD and high all-cause mortality observed in
this study population.
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Study design and subject disposition based on CMV viremia and EOD.
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Table 1
Subject characteristics by study step
Characteristic Step 1 (N = 338) Step 2 (N = 47) Step 3 (N = 18)
% Male 88% 94% 100%
% Black, non-Hispanic 30% 15% 11%
% White, Non-Hispanic 56% 60% 67%
% Hispanic 13% 26% 22%
Median age, years 42 46 43
Median CD4+ cell count, /mm3 30 12 8
Median HIV RNA copies/mL 96,420 – –
% not receiving HAART 19.5% 21.3% 22.2%

















Confirmed CMV retinitis Typical lesions including white areas with or without hemorrhages and/or gray-white areas of retinal
necrosis with or without hemorrhages. Lesion(s) has/have irregular, dry-appearing, granular border, with
little or no overlying vitreous inflammation. Must be diagnosed by an experienced ophthalmologist using
indirect ophthalmoscopy and documented by retinal photography that can be independently verified.
Probable CMV retinitis Typical lesions including white areas with or without hemorrhages and/or gray-white areas of retinal
necrosis with or without hemorrhages. Lesion(s) has/have irregular, dry-appearing, granular border, with
little or no overlying vitreous inflammation. Must be diagnosed by an experienced ophthalmologist using
indirect ophthalmoscopy but is not documented by retinal photographs.
Confirmed CMV esophagitis • Presence of at least one of the following symptoms: retrosternal pain or odynophagia (pain on
swallowing).
AND
• Appropriate visualization procedure (endoscopy) that reveals mucosal erythema, erosion, or
ulceration.
AND
• Tissue biopsy demonstrating CMV by antigen or characteristic cytopathic changes.
Probable CMV esophagitis • Presence of at least one of the following symptoms: retrosternal pain or odynophagia (pain on
swallowing).
AND
• Appropriate visualization procedure (endoscopy) that reveals mucosal erythema, erosion, or
ulceration.
AND
• CMV is isolated from the lesion.
AND
• Anti-CMV therapy initiated or recommended.
Confirmed CMV gastroenteritis • Presence of abdominal pain.
AND
• Appropriate visualization procedure (endoscopy) that reveals mucosal erythema, erosion, or
ulceration.
AND
• Tissue biopsy demonstrating CMV by antigen or characteristic cytopathic changes.
Probable CMV gastroenteritis • Presence of abdominal pain.
AND
• Appropriate visualization procedure (endoscopy) that reveals mucosal erythema, erosion, or
ulceration.
AND
• CMV is isolated from the lesion.
AND
• Anti-CMV therapy initiated or recommended.
Confirmed CMV colitis • Presence of at least one of the following symptoms: abdominal pain or diarrhea (typically in
small volume and associated with mucus and blood).
AND
• Appropriate visualization procedure (colonoscopy, sigmoidoscopy, or endoscopy) that reveals
mucosal erythema, erosion, or ulceration.
AND
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CMV endpoint Definition
• Tissue biopsy demonstrating CMV by antigen or characteristic cytopathic changes.
Probable CMV colitis • Presence of at least one of the following symptoms: abdominal pain or diarrhea (typically in
small volume and associated with mucus and blood).
AND
• Appropriate visualization procedure (colonoscopy, sigmoidoscopy, or endoscopy) that reveals
mucosal erythema, erosion, or ulceration.
AND
• CMV is isolated from the lesion.
AND
• Anti-CMV therapy initiated or recommended.
Confirmed CMV proctitis • Presence of rectal pain, often associated with tenesmus, mucus, and blood.
AND
• Appropriate visualization procedure (colonoscopy, sigmoidoscopy, or proctoscopy) that
reveals mucosal erythema, erosion, or ulceration
AND
• Tissue biopsy demonstrating CMV by antigen or characteristic cytopathic changes.
Probable CMV proctitis • Presence of rectal pain, often associated with tenesmus, mucus, and blood.
AND
• Appropriate visualization procedure (colonoscopy, sigmoidoscopy, or proctoscopy) that
reveals mucosal erythema, erosion, or ulceration.
AND
• CMV is isolated from the lesion.
AND
• Anti-CMV therapy initiated or recommended.
Confirmed CMV pneumonitis • Hypoxemia and infiltrates on chest X-ray or CT/MRI scan.
AND
• Tissue biopsy or cells obtained by BAL demonstrating CMV by antigen or characteristic
cytopathic changes.
AND
• No other pathogens identified by routine testing (see instructions) OR signs/symptoms persist
or recur after treatment of copathogens.
Probable CMV pneumonitis • Hypoxemia and infiltrates on chest X-ray or CT/MRI scan.
AND
• Positive CMV culture or detection of CMV antigen from fluid obtained by BAL.
AND
• No other pathogens identified by routine testing (see instructions) OR signs/symptoms persist
or recur after treatment of copathogens.
AND
• Anti-CMV therapy initiated or recommended.
Confirmed CMV encephalitis • Progressive change in mental status, delirium, rapidly progressive cognitive impairment, or
signs and symptoms of brain stem injury.
AND
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CMV endpoint Definition
• Detection of viral nucleic acids (e.g., PCR) in CSF or CSF CMV culture positive or brain
biopsy demonstrating CMV by antigen, detection of viral nucleic acids (e.g., PCR), or
characteristic cytopathic changes.
Probable CMV encephalitis • Progressive change in mental status, delirium, rapidly progressive cognitive impairment, or
signs and symptoms of brain stem injury.
AND
• MRI or contrast CT scan performed which: a) excludes toxoplasmosis, lymphoma, PML, or
other intracranial process, and b) demonstrates periventricular inflammation or meningeal
enhancement.
AND
• Other etiologies ruled out.
AND
• CMV EOD (e.g., retinitis, colitis) present.
AND
• Specific therapy initiated, changed, or recommended.
Confirmed other CMV syndromes Hepatitis or cholangitis:
• ALP or ALT significantly elevated above the patient’s baseline values
AND
• Tissue biopsy demonstrating CMV by antigen or characteristic cytopathic changes.
Radiculomyelopathy:
• Clinical presentation compatible with CMV EOD, including all of the following:
a. Decreased lower extremity strength and reflexes or syndrome consistent with a
cord lesion presently subacutely (over days to weeks);
b. Myelogram or MRI reveals no mass lesions but lower spinal nerve roots thickened;
c. CMV-positive culture in CSF OR detection of CMV viral nucleic acids (e.g., PCR)
in CSF.
Confirmed cutaneous CMV ulcers • Direct visualization of oral or vulvovaginal or perianal ulcers.
AND
• CMV culture of lesion or histologic demonstration of typical CMV cytopathology on biopsy
of lesion.
CMV diagnosis not otherwise
defined in the ACTG criteria for
clinical events, Appendix 50
To report a diagnosis that does not meet the definition on a specific Clinical Event Form, follow the Clinical
Event Guidelines in the AACTG Forms Manual for unusual diagnostic cases by completing the specific
Clinical Event Form, CESUM10 Form - Clinical Event Summary (Uncommon Events) with a detailed
explanation of the diagnosis in the comments section and FAX to the DMC Data Manager for the study.
(See Study Management Section for contact information.) In both cases, the form will be reviewed by the
Protocol Team and the site will be informed of the Team’s decision concerning the diagnosis.
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